NGMS, US64049M2098

NeoGenomics stock trades at EUR 17.04 after Q2 EPS beat

Published on 09/29/2026 at 15:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NeoGenomics stock posted Q2 revenue of USD 201.66 million, up 11.20 percent year over year. EPS reached USD 0.05 versus USD 0.03 consensus.

NGMS, US64049M2098, Illustration mit AI erstellt.

NeoGenomics (ISIN US64049M2098) was trading at EUR 17.04 at Lang & Schwarz on September 29, 2026, at 3:03 p.m. CEST, down 0.06 percent from the prior close of EUR 17.05. The latest results showed quarterly EPS of USD 0.05 against USD 0.03 consensus, keeping the company at the center of the current valuation debate.

Q2 revenue reaches USD 201.66 million

According to MarketBeat on September 11, 2026, NeoGenomics reported USD 201.66 million in Q2 2026 revenue, up 11.20 percent year over year. Quarterly EPS of USD 0.05 exceeded the USD 0.03 consensus estimate by USD 0.02.

The result marked a clear improvement in the earnings line: the company posted USD 0.03 EPS in the same period a year earlier, while the latest quarter moved to USD 0.05. NeoGenomics' investor-relations page identifies July 28, 2026, as the release date for its Q2 2026 results.

NGS revenue grows 26 percent

At the Morgan Stanley healthcare conference on September 15, 2026, management described next-generation sequencing and minimal residual disease testing as the main growth engines. Investing.com reported that NGS revenue grew 26 percent in the first half of 2026 and exceeded USD 250 million on an annualized basis.

The mix matters because higher-value testing is expanding faster than the broader business. Management also linked the strategy to the August 2026 Medicare coverage decision for the RaDaR ST assay, which broadens the company's oncology testing proposition across several cancer types.

Analyst target remains a key checkpoint

MarketBeat reported a Moderate Buy consensus from 10 firms on September 11, 2026, with an average 12-month target of USD 17.67. Needham raised its target from USD 15.00 to USD 19.00 on July 29, 2026, while Craig Hallum maintained a USD 19.00 target.

The USD targets and the euro quotation serve different market references, so the intraday Lang & Schwarz move should be read separately from the analyst snapshot. The next earnings report is scheduled for October 27, 2026, giving investors a defined checkpoint for the revenue and margin trend.

NeoGenomics stock holds at EUR 17.04

NeoGenomics stock was trading at EUR 17.04 at Lang & Schwarz on September 29, 2026, at 3:03 p.m. CEST. The quote was down 0.06 percent versus the Lang & Schwarz prior close of EUR 17.05.